Table 3

DAA combinations used in the treatment of recently acquired and chronic HCV infection

ProductComponentsAdministrationDuration of treatmentMost common adverse effects
NS5A inhibitorProtease inhibitorPolymerase inhibitor
Pan-genotypic (G1–6) drug combinations
EpclusaVelpatasvir 100 mgSofosbuvir 400 mg1 tablet once daily12 weeksHeadache
Gastrointestinal symptoms (nausea, diarrhoea)
MaviretPibrentasvir 40 mgGlecaprevir 100 mg3 tablets once daily8 weeks
12 weeks (if treatment experienced and cirrhotic)
Genotype-specific (G1 or G4) drug combinations
HarvoniLedipasvir 90 mgSofosbuvir 400 mg1 tablet once daily8–12 weeks
ZepatierElbasvir 50 mgGrazoprevir 100 mg1 tablet once daily12 weeks
Retreatment after first-line DAA failure
VoseviVelpatasvir 100 mgVoxilaprevir 100 mgSofosbuvir 400 mg1 tablet once daily12 weeks
  • DAA, direct acting antiviral.